Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 10/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301745 | 1.00 | LMNA (0.69) | LMNAMAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL4433632 | 0.96 | LMNA (0.74) | LMNAMAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL953126 | 0.86 | LMNA (0.61) | LMNAMAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL30301712 | 0.85 | MAPT (0.65) | LMNAMAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL6629173 | 0.85 | MAPT (0.65) | LMNAMAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL1902475 | 0.85 | MEN1 (0.63) | LMNAMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL105883 | 0.84 | MAPT (0.56) | LMNAMAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL7985113 | 0.83 | ALDH1A1 (0.64) | LMNAMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL4434853 | 0.83 | MAPT (0.60) | LMNAMAPK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL13075783 | 0.82 | ALDH1A1 (0.48) | LMNAMAPK1L3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4182311-B1 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | EXONATE LTD (GB) | 2025-06-04 | — | — | EP | disclosed |
| US-20240300929-A1 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | EXONATE LTD (GB) | 2024-09-12 | — | — | US | disclosed |
| US-12024504-B2 | 1-methyl-1H-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | EXONATE LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20220411412-A1 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | EXONATE LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| WO-2022013555-A1 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | EXONATE LIMITED (GB) | 2022-01-20 | — | — | WO | disclosed |
| EP-2424858-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-14 | — | — | EP | disclosed |
| US-8362249-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| EP-2424858-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126851-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411412-A1 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | VEGFA, FLT4, FLT1 | LMNA 2008/4885MAPK1 1321/4885L3MBTL1 1820/4885 |
| US-20240300929-A1 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | VEGFA, FLT4, FLT1 | LMNA 2008/4885MAPK1 1321/4885L3MBTL1 1820/4885 |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | LMNA 3677/4885MAPK1 1970/4885L3MBTL1 3190/4885 |
| US-12024504-B2 | 1-methyl-1H-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | VEGFA, FLT4, FLT1 | LMNA 2008/4885MAPK1 1321/4885L3MBTL1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.